Gilead Retained Earnings from 2010 to 2025

GILD Stock

USD 111.03 3.14 2.91%

Gilead Sciences' Retained Earnings are increasing over the years with slightly volatile fluctuation. Retained Earnings are expected to dwindle to about 6.2 B. Retained Earnings is the cumulative amount of net income that Gilead Sciences retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

1991-03-31

Previous Quarter

11.1 B

Current Value

11.5 B

Quarterly Volatility

7.7 B

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Gilead Sciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Gilead Sciences' main balance sheet or income statement drivers, such as Interest Expense of 549.9 M, Total Revenue of 30.2 B or Gross Profit of 23.6 B, as well as many indicators such as Price To Sales Ratio of 3.81, Dividend Yield of 0.0269 or PTB Ratio of 7.83. Gilead financial statements analysis is a perfect complement when working with Gilead Sciences Valuation or Volatility modules.

Check out the analysis of Gilead Sciences Correlation against competitors.

For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.

Latest Gilead Sciences' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Gilead Sciences over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Gilead Sciences' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Gilead Sciences' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 11.5 B

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

Gilead Retained Earnings Regression Statistics

	Arithmetic Mean	12,394,985,962
	Coefficient Of Variation	53.81
	Mean Deviation	5,632,142,548
	Median	15,687,000,000
	Standard Deviation	6,669,575,578
	Sample Variance	44483238.4T
	Range	19.4B
	R-Value	0.48
	Mean Square Error	36755015T
	R-Squared	0.23
	Significance	0.06
	Slope	670,114,928
	Total Sum of Squares	667248575.8T

Gilead Retained Earnings History

	2025	6.2 B
	2024	11.5 B
	2023	16.3 B
	2022	15.7 B
	2021	16.3 B
	2020	14.4 B
	2019	19.4 B

Other Fundumenentals of Gilead Sciences

Retained Earnings Total Equity

Gilead Sciences Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Net Receivables	Short Term Investments	Long Term Debt	Capital Stock	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Total Permanent Equity	Good Will	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Intangible Assets	Short Long Term Debt	Net Invested Capital	Net Working Capital
Total Assets		0.95	0.53	0.84	-0.05	0.99	0.62	0.8	0.76	0.48	0.93	0.24	0.24	0.85	-0.78	-0.52	0.81	0.68	0.96	-0.2	0.69	0.18	0.74	0.23	-0.56	-0.48
Total Stockholder Equity	0.95		0.39	0.87	0.07	0.9	0.63	0.69	0.79	0.43	0.84	0.42	0.42	0.81	-0.66	-0.39	0.69	0.58	0.89	-0.24	0.63	0.17	0.66	0.22	-0.54	-0.39
Net Debt	0.53	0.39		0.49	-0.12	0.57	0.27	0.7	0.24	0.4	0.61	-0.18	-0.18	0.34	-0.62	-0.41	0.57	0.33	0.55	0.15	0.38	0.17	0.61	0.29	-0.06	-0.35
Retained Earnings	0.84	0.87	0.49		0.08	0.8	0.82	0.59	0.82	0.57	0.89	0.34	0.34	0.51	-0.52	-0.11	0.53	0.25	0.85	-0.42	0.45	0.43	0.49	0.31	-0.14	-0.12
Accounts Payable	-0.05	0.07	-0.12	0.08		-0.09	0.23	-0.2	0.26	-0.12	0.03	0.46	0.46	-0.27	0.41	0.27	-0.44	-0.42	0.04	-0.23	-0.35	0.29	-0.13	0.22	0.41	0.27
Total Liab	0.99	0.9	0.57	0.8	-0.09		0.59	0.83	0.72	0.48	0.93	0.16	0.16	0.85	-0.8	-0.55	0.84	0.7	0.96	-0.17	0.69	0.18	0.75	0.23	-0.56	-0.51
Total Current Assets	0.62	0.63	0.27	0.82	0.23	0.59		0.43	0.57	0.74	0.73	0.2	0.2	0.2	-0.3	0.32	0.34	-0.1	0.69	-0.69	0.11	0.67	0.01	0.46	0.1	0.32
Short Term Debt	0.8	0.69	0.7	0.59	-0.2	0.83	0.43		0.33	0.62	0.75	-0.07	-0.07	0.74	-0.88	-0.51	0.86	0.64	0.77	0.07	0.71	-0.04	0.64	0.14	-0.55	-0.36
Net Receivables	0.76	0.79	0.24	0.82	0.26	0.72	0.57	0.33		0.09	0.8	0.51	0.51	0.53	-0.31	-0.31	0.34	0.35	0.76	-0.26	0.34	0.32	0.58	0.21	-0.15	-0.4
Short Term Investments	0.48	0.43	0.4	0.57	-0.12	0.48	0.74	0.62	0.09		0.51	-0.03	-0.03	0.18	-0.59	0.23	0.43	0.0	0.5	-0.44	0.21	0.28	0.0	0.1	-0.05	0.37
Long Term Debt	0.93	0.84	0.61	0.89	0.03	0.93	0.73	0.75	0.8	0.51		0.16	0.16	0.68	-0.69	-0.39	0.72	0.5	0.97	-0.22	0.55	0.36	0.65	0.33	-0.28	-0.37
Capital Stock	0.24	0.42	-0.18	0.34	0.46	0.16	0.2	-0.07	0.51	-0.03	0.16		1.0	0.12	0.03	0.0	-0.12	-0.02	0.24	-0.29	-0.02	-0.01	0.19	-0.02	0.04	0.0
Common Stock	0.24	0.42	-0.18	0.34	0.46	0.16	0.2	-0.07	0.51	-0.03	0.16	1.0		0.12	0.03	0.0	-0.12	-0.02	0.24	-0.29	-0.02	-0.01	0.19	-0.02	0.04	0.0
Property Plant Equipment	0.85	0.81	0.34	0.51	-0.27	0.85	0.2	0.74	0.53	0.18	0.68	0.12	0.12		-0.78	-0.74	0.88	0.93	0.76	0.17	0.81	-0.19	0.77	0.05	-0.87	-0.74
Current Deferred Revenue	-0.78	-0.66	-0.62	-0.52	0.41	-0.8	-0.3	-0.88	-0.31	-0.59	-0.69	0.03	0.03	-0.78		0.62	-0.84	-0.77	-0.72	-0.18	-0.71	0.22	-0.71	0.16	0.61	0.5
Net Tangible Assets	-0.52	-0.39	-0.41	-0.11	0.27	-0.55	0.32	-0.51	-0.31	0.23	-0.39	0.0	0.0	-0.74	0.62		-0.58	-0.89	-0.43	-0.58	-0.64	0.48	-0.89	0.24	0.64	0.94
Total Permanent Equity	0.81	0.69	0.57	0.53	-0.44	0.84	0.34	0.86	0.34	0.43	0.72	-0.12	-0.12	0.88	-0.84	-0.58		0.81	0.77	0.06	0.75	0.02	0.63	0.29	-0.73	-0.55
Good Will	0.68	0.58	0.33	0.25	-0.42	0.7	-0.1	0.64	0.35	0.0	0.5	-0.02	-0.02	0.93	-0.77	-0.89	0.81		0.58	0.41	0.76	-0.39	0.81	-0.14	-0.86	-0.87
Long Term Debt Total	0.96	0.89	0.55	0.85	0.04	0.96	0.69	0.77	0.76	0.5	0.97	0.24	0.24	0.76	-0.72	-0.43	0.77	0.58		-0.29	0.57	0.33	0.67	0.33	-0.39	-0.41
Capital Surpluse	-0.2	-0.24	0.15	-0.42	-0.23	-0.17	-0.69	0.07	-0.26	-0.44	-0.22	-0.29	-0.29	0.17	-0.18	-0.58	0.06	0.41	-0.29		0.25	-0.73	0.33	-0.46	-0.27	-0.55
Deferred Long Term Liab	0.69	0.63	0.38	0.45	-0.35	0.69	0.11	0.71	0.34	0.21	0.55	-0.02	-0.02	0.81	-0.71	-0.64	0.75	0.76	0.57	0.25		-0.4	0.71	-0.09	-0.76	-0.55
Long Term Investments	0.18	0.17	0.17	0.43	0.29	0.18	0.67	-0.04	0.32	0.28	0.36	-0.01	-0.01	-0.19	0.22	0.48	0.02	-0.39	0.33	-0.73	-0.4		-0.26	0.78	0.43	0.34
Intangible Assets	0.74	0.66	0.61	0.49	-0.13	0.75	0.01	0.64	0.58	0.0	0.65	0.19	0.19	0.77	-0.71	-0.89	0.63	0.81	0.67	0.33	0.71	-0.26		-0.11	-0.53	-0.83
Short Long Term Debt	0.23	0.22	0.29	0.31	0.22	0.23	0.46	0.14	0.21	0.1	0.33	-0.02	-0.02	0.05	0.16	0.24	0.29	-0.14	0.33	-0.46	-0.09	0.78	-0.11		0.11	0.12
Net Invested Capital	-0.56	-0.54	-0.06	-0.14	0.41	-0.56	0.1	-0.55	-0.15	-0.05	-0.28	0.04	0.04	-0.87	0.61	0.64	-0.73	-0.86	-0.39	-0.27	-0.76	0.43	-0.53	0.11		0.62
Net Working Capital	-0.48	-0.39	-0.35	-0.12	0.27	-0.51	0.32	-0.36	-0.4	0.37	-0.37	0.0	0.0	-0.74	0.5	0.94	-0.55	-0.87	-0.41	-0.55	-0.55	0.34	-0.83	0.12	0.62

Click cells to compare fundamentals

About Gilead Sciences Financial Statements

Gilead Sciences stakeholders use historical fundamental indicators, such as Gilead Sciences' Retained Earnings, to determine how well the company is positioned to perform in the future. Although Gilead Sciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Gilead Sciences' assets and liabilities are reflected in the revenues and expenses on Gilead Sciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Gilead Sciences. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Retained Earnings	11.5 B	6.2 B
Retained Earnings Total Equity	18 B	12.7 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:

How To Invest In Gilead

Details

Is Gilead Stock a good investment?

Details

What is Gilead Sciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Gilead Sciences Correlation against competitors.

For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.

You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.248

Dividend Share

3.08

Earnings Share

0.38

Revenue Per Share

23.059

Quarterly Revenue Growth

0.064

The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Gilead Retained Earnings from 2010 to 2025

Latest Gilead Sciences' Retained Earnings Growth Pattern

Gilead Retained Earnings Regression Statistics

Gilead Retained Earnings History

Other Fundumenentals of Gilead Sciences

Gilead Sciences Retained Earnings component correlations

About Gilead Sciences Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY